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Genetic sharing and heritability of paediatric
age of onset autoimmune diseases
Yun R. Li1,2, Sihai D. Zhao3, Jin Li1, Jonathan P. Bradﬁeld1, Maede Mohebnasab1, Laura Steel1, Julie Kobie4, Debra J. Abrams1,
Frank D. Mentch1, Joseph T. Glessner1, Yiran Guo1, Zhi Wei1,5, John J. Connolly1, Christopher J. Cardinale1, Marina Bakay1,
Dong Li1, S. Melkorka Maggadottir1,6, Kelly A. Thomas1, Haijun Qui1, Rosetta M. Chiavacci1, Cecilia E. Kim1, Fengxiang Wang1,
James Snyder1, Berit Flatø7, Øystein Førre7, Lee A. Denson8, Susan D. Thompson9, Mara L. Becker10, Stephen L. Guthery11,
Anna Latiano12, Elena Perez13, Elena Resnick14, Caterina Strisciuglio15, Annamaria Staiano15, Erasmo Miele15, Mark S. Silverberg16,
Benedicte A. Lie17, Marilynn Punaro18, Richard K. Russell19, David C. Wilson20, Marla C. Dubinsky21, Dimitri S. Monos22,23,
Vito Annese24, Jane E. Munro25,26, Carol Wise27, Helen Chapel28, Charlotte Cunningham-Rundles14, Jordan S. Orange29,
Edward M. Behrens23,30, Kathleen E. Sullivan6,23, Subra Kugathasan31, Anne M. Grifﬁths32, Jack Satsangi33, Struan F.A. Grant1,23,
Patrick M.A. Sleiman1,23, Terri H. Finkel34, Constantin Polychronakos35, Robert N. Baldassano23,36, Eline T. Luning Prak37,
Justine A. Ellis38,39, Hongzhe Li4, Brendan J. Keating1,23 & Hakon Hakonarson1,23,40
Autoimmune diseases (AIDs) are polygenic diseases affecting 7–10% of the population in the Western
Hemisphere with few effective therapies. Here, we quantify the heritability of paediatric AIDs (pAIDs),
including JIA, SLE, CEL, T1D, UC, CD, PS, SPA and CVID, attributable to common genomic variations (SNP-
h2). SNP-h2 estimates are most signiﬁcant for T1D (0.863±s.e. 0.07) and JIA (0.727±s.e. 0.037), more
modest for UC (0.386±s.e. 0.04) and CD (0.454±0.025), largely consistent with population estimates
and are generally greater than that previously reported by adult GWAS. On pairwise analysis, we observed
that the diseases UC-CD (0.69±s.e. 0.07) and JIA-CVID (0.343±s.e. 0.13) are the most strongly cor-
related. Variations across the MHC strongly contribute to SNP-h2 in T1D and JIA, but does not signiﬁcantly
contribute to the pairwise rG. Together, our results partition contributions of shared versus disease-speciﬁc
genomic variations to pAID heritability, identifying pAIDs with unexpected risk sharing, while recapitulating
known associations between autoimmune diseases previously reported in adult cohorts.
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A
utoimmune (AI) diseases affect approximately 1 in 12
individuals living in the Western Hemisphere, represent-
ing a signiﬁcant cause of morbidity, chronic disability and
health-care burden. High rates of sibling recurrence and twin–
twin concordance, both within and across multiple independent
AI diseases, coupled with recent results from genome-wide
association studies (GWAS), suggest that a set of shared genetic
risk factors underlie paediatric AI disease (pAID) aetiology1–3.
Moreover, a number of AI diseases show clear familial clustering,
such as inﬂammatory bowel disease (IBD)4, whereas others (for
example, type 1 diabetes (T1D), AI thyroiditis (THY) and celiac
disease (CEL) may manifest as comorbid diseases in
polyglandular AI syndromes2. Although the concept of genetic
sharing among AIs is intriguing, it remains unclear if this is due
to ‘pleiotropic’ risk factors that predispose to multiple AI diseases
via shared mechanisms or if multiple, independent risk factors are
responsible.
GWAS have identiﬁed single-nucleotide polymorphisms
(SNPs) across hundreds of loci as being associated with an
increased risk of developing AI5–12. These ﬁndings, coupled with
those from epidemiological studies, strongly support the existence
of (i) an overlapping ‘AI disease genetic landscape’13,14 and
(ii), consequently, a shared heritability across these diseases.
Heritability, in the broad-sense (H2), is deﬁned as the entirety of
an individual’s phenotypic variation explained by genetic
variance, but in practicality, it can be difﬁcult to quantify and
partition precisely15. A major contribution to H2 is the narrow-
sense or additive heritability (h2), which can be more accurately
quantiﬁed.15. Recently, a new method was established to estimate
the total phenotype variance attributable to additive genetic
variations using genome-wide SNP genotyping data16–19. The
method has been since applied to dozens of GWAS-examined
traits and extended to examine jointly the co-heritability of
related diseases20.
We systematically quantiﬁed the narrow-sense heritability, h2,
as well as the pairwise joint heritability of pAIDs attributable to
common genomic variation using a single-centre accrued cohort
of over 5,000 unrelated cases composed of nine independent
pAIDs and 36,000 shared, population-based healthy controls. We
ﬁrst report the genome-wide SNP genotype-derived heritability
estimates (referred to as SNP-h2) and then the genetic correlation
(SNP-rG) across pairs of the nine investigated pAIDs. We
contextualize these ﬁndings alongside a comprehensive review of
available literature and epidemiological data sets, illustrate a
method for quantifying genetic risk factor sharing across pAIDs,
and provide considerations for how such genetic data can aid
disease prediction.
Results
Quantifying the heritability of paediatric AI diseases. To
quantify the SNP-h2 of the nine pAIDs, we utilized genome-wide
SNP genotypes ascertained from DNA samples of patients of
each pAID cohort along with samples from population-based
control subjects with no known diagnosis of autoimmunity
or immunodeﬁciency. Following extensive quality control (QC),
removing SNPs of lower minor allele frequency (MAF),
missingness and differential missingness in cases and controls,
and deviation from Hardy–Weinberg equilibrium (see Methods),
we retained 461,301 SNPs. We excluded samples for low geno-
typing rates, cryptic relatedness and genetic outliers, leaving a
cohort consisting of 4,956 cases distributed across nine pAIDs
and 27,451 unrelated shared population-based controls (Table 1).
We also included, for comparison, a non-immune-mediated
dichotomous trait, paediatric-onset epilepsy (EPI); this cohort of
B800 case subjects was recruited and genotyped at our centre
using the same platforms over the same time period.
We used a previously described method for estimating disease
variance explained by additive genetic factors using GWAS data
(referred to as SNP-based heritability or SNP-h2)17. We
transformed the SNP-h2 estimates from the observed to the
liability-scale using respective observed disease prevalence. To
assess if our SNP-h2 estimates are consistent with previously
published ﬁndings and other population-based heritability
estimates (POP-h2), we performed a systematic literature search
followed by manual curation of prevalence and heritability
estimates for each of the nine pAIDs (Fig. 1a and Supplementary
Tables 1 and 2).
Among the pAIDs examined where the SNP-h2 estimates were
at least nominally signiﬁcant (Po0.05), T1D and juvenile
idiopathic arthritis (JIA) were the most highly heritable
(Fig. 1b). Considerably lower estimates were observed for
ulcerative colitis (UC) and Crohn’s disease (CD; Supplementary
Fig. 1A), suggesting that environmental factors may play a much
larger role in IBD aetiology (Fig. 1d). We also observed relatively
low SNP-h2 estimates for systemic lupus erythematosus (SLE;
0.205±s.e. 0.076).
Contribution of the MHC region and ChrX to SNP-h2. Given
the known association of variants across the MHC with AI
diseases, we quantiﬁed their contribution to the SNP-h2 for each
of the nine pAIDs. We ﬁrst performed HLA imputation21, to
identify the most strongly associated SNP, amino acid or HLA
allele with each pAID (Supplementary Table 5) and we estimated
POP-h2 attributable to the extended MHC based on previous
analyses (Supplementary Tables 6 and 7). The MHC-speciﬁc
SNP-h2 estimates correlated well with the strength of lead MHC
P-value. For example, variations across the extended MHC region
accounted for 32.7% of the total autosomal SNP-h2 in T1D
and 24.7% of that in CEL, with no signiﬁcant contribution to the
SNP-h2 estimates in psoriasis (PS), SLE, CD or the non-pAID,
EPI. Despite the pervasive association between SNPs within the
MHC and both JIA and UC, contributions of the extended MHC
to their total SNP-h2 (10.7% and 5.8%, respectively) were limited
(Fig. 1c and Table 2). Despite the known association with
HLA-DRB1*0103 and HLA-B*52 in UC13, we observed that
removing the extended MHC did not signiﬁcantly reduce the
observed SNP-h2 for either UC or, the related IBD phenotype, CD
(Supplementary Table 8). As expected, the contribution of ChrX
to the overall SNP-h2 was small across all pAIDs (Supplementary
Table 2). These estimates are consistent with expectations as
Table 1 | Summary of cohorts included.
Disease Full disease name Cases Controls GIF* Prevalencew
CD Crohn’s disease 1,848 27,457 1.086 3.00E03
CEL Celiac disease 137 27,435 1.006 1.00E02
CVID Common variable
immunodeﬁciency
disorder
304 27,492 1.010 1.00E04
EPI Epilepsy 754 26,122 1.027 1.00E04
JIA Juvenile idiopathic
arthritis
1,112 27,131 1.000 2.00E03
PS Psoriasis 85 27,474 1.012 1.00E03
SLE Systemic lupus
erythematosus
252 27,525 1.019 1.00E04
SPA Spondyloarthropathy 98 27,483 1.020 1.00E04
T1D Type 1 diabetes 664 27,395 1.062 5.00E03
UC Ulcerative colitis 854 27,482 1.041 1.00E03
GIF, genomic inﬂation factor; SNP, single-nucleotide polymorphism.
*GIF is provided for each cohort and included all SNPs (including ChrX and the extended MHC).
wPrevalence estimates used here are those made based on observations at our center.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms9442
2 NATURE COMMUNICATIONS | 6:8442 |DOI: 10.1038/ncomms9442 | www.nature.com/naturecommunications
& 2015 Macmillan Publishers Limited. All rights reserved.
ChrX makes up only about 5% of the total genome22, has
comparatively fewer coding bases and is less polymorphic23.
Disease prediction using support vector machines (SVM)s.
Given that we observed relatively high rates of heritability across
many of the pAIDs, we evaluated the utility of common genomic
variations in predicting pAID disease risk, using a SVM model-
based approach. Using a tenfold cross-validation study design, we
built a linear SVM model using the top GWAS signals observed
using nine out of ten of the total samples and tested this
SVM predictor in the remaining 10% of the samples. Based on
previous analyses in both case–control24 and quantitative traits25,
we expect that disease prediction accuracy to behave as function
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Figure 1 | Autoimmune disease prevalence and heritability estimates. (a) Mean population-based AI disease prevalence (orange) and heritability (blue)
estimates (mean±s.d.). Data are curated from epidemiological surveys among Caucasian populations in Europe or North America based on studies
indexed in PubMed between 1975 and 2015. Where multiple sources of data are available for a given trait, we reported a simple non-weighted arithmetic
mean and provided as error bars the standard deviation. Most heritability estimates were based on twin concordance rates. Raw data used and references
can be found in Supplementary Tables 1 and 2. (b) Univariate SNP-heritability (SNP-h2, orange) compared with estimates reported by prior studies. (SNP-h2
(lit), blue) based on variations across the autosomes compared with population-based estimates (POP-h2, red) as reported in the literature (lit). Raw data
used from prior GWAS SNP-h2 estimates are provided in Supplementary Table 3. Error bars denote standard error. (c) Univariate SNP-heritability
(autosomal) estimates with (Light green, wide) and without the extended MHC (orange, narrow). Results are compared with corresponding heritability
estimates reported using population-based (red, narrow) versus other published SNP-heritability estimates (blue, narrow), when available for a given
disease. Literature data used and references can be found in Supplementary Table 2 and Supplementary Tables 6 and 7. Error bars denote standard error.
(d) Partitioning phenotypic variance to genetic and non-genetic (ENV, green) components in the four largest pAID cohorts. Genetic components include
contributions from the entire autosomal regions excluding the MHC (exMHC, orange), the extended MHC (MHC, blue) alone as well as from the
X-chromosome (ChrX, red).
Table 2 | Contribution of autosomal, autosomal with extended MHC removed (exMHC) and ChrX variations to pAID
heritability (h2).
Disease h2(auto) s.e. P h2(exMHC) s.e. P %MHC* ChrX s.e. P
CD 0.454 0.025 o1.00E–04 0.447 0.025 o1.00E–04 1.54 0.014 0.004 2.35E–04
CEL 0.447 0.362 1.06E–01 0.337 0.361 1.74E–01 24.72 0.048 0.058 1.89E–01
CVIDw 0.181 0.063 1.72E–03 0.167 0.063 3.66E–03 8.12 NA NA NA
EPI 0.168 0.027 1.05E–10 0.163 0.027 3.90E–10 2.91 0.010 0.005 1.21E–02
JIA 0.727 0.037 o1.00E–04 0.650 0.037 o1.00E–04 10.66 0.027 0.007 4.91E–06
PS 0.949 0.381 5.90E–03 0.949 0.380 5.87E–03 0.02 0.003 0.061 4.82E–01
SLE 0.206 0.076 3.16E–03 0.202 0.076 3.74E–03 1.89 0.013 0.013 1.60E–01
SPA 0.370 0.192 2.45E–02 0.310 0.191 4.91E–02 16.17 0.029 0.028 1.74E–01
T1D 0.863 0.070 o1.00E–04 0.581 0.069 o1.00E–04 32.66 0.028 0.012 5.27E–03
UC 0.386 0.041 o1.00E–04 0.363 0.041 o1.00E–04 5.84 0.012 0.007 3.38E–02
CD, crohn’s disease; CEL, celiac disease; CVID, common variable immunodeﬁciency disorder; EPI, epilepsy; JIA, juvenile idiopathic arthritis; NA, not applicable; pAID, paediatric autoimmune disease; PS,
psoriasis; SLE, systemic lupus erythematosus; SPA, spondyloarthropathy; T1D, type 1 diabetes; UC, ulcerative colitis.
P-values (P) are based on results from the restricted maximum likelihood estimate (likelihood ratio test). Error bars represent standard error.
*Percentage contribution of the extended MHC to total autosomal SNP-h2
wREML estimates could not be made due to limited common SNP variability among this cohort on the X-chromosome
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of heritability, sample size and the number of causal variants.
We assessed the mean and maximum area under the receiver
operating characteristic curve (AUC) achieved, showing that
our SVM predictor was most effective for JIA and T1D
(AUCmax40.9; AUCmean40.85), although satisfactory results
was also seen in CEL (AUCmax40.8 and AUCmean40.7). These
ﬁndings are consistent with that recently reported by Speed et al.
using an independent adult CEL cohort26. The predictability of all
nine pAIDs was fairly robust to range of P-value thresholds used
for selecting SNP predictors in building the SVM model (Fig. 3
and Supplementary Table 11).
Estimation of pairwise co-heritability across pAIDs. To
investigate diseases with shared underlying genetic risk factors,
we assessed the genetic correlation (rG) for each pair of pAIDs
and between each of the nine pAIDs and EPI, which provided a
comparative baseline for non-signiﬁcant genetic correlation20.
We used both a strict (PBS) and a more relaxed Bonferroni
correction (PBL) to adjust for either 45 (all pairwise
combinations) or 9 comparisons (combinations per pAID); (see
Methods). We observed the highest rG between UC and CD
(rG¼ þ 0.66; PBSo0.001), consistent with the reported sharing
of association loci by several published GWAS, immunochip and
ﬁne-mapping studies11,27–29 (Supplementary Table 10). We also
noted a positive rG between common variable immunodeﬁciency
disorder (CVID) and JIA (rG¼ þ 0.34), although it was more
modest (PBLo0.01). While we did observe a marginally positive
rG for CD and T1D consistent with results from published
GWAS metanalysis30, although it did not reach signiﬁcance at a
liberal Bonferroni threshold (rG¼ þ 0.096; PBL¼ 0.17). Of note,
we did not observe a signiﬁcant reduction in rG estimates when
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Figure 2 | Prevalence of AI disease co-morbidities and estimates of genetic correlation (co-heritability) across pAIDs. (a) Observed prevalence of pAID
comorbidity observed in Caucasian populations in Europe and North America as curated from large-scale cohort studies. For each pairwise combination
(for example, Disease 1–Disease 2), the rate (y axis) indicates the percentage of patients with Disease 2 who have also been diagnosed with Disease 1.
Literature data used and references can be found in Supplementary Table 9. (b) Bivariate estimates of genetic correlation (pairwise co-heritability) across
pAIDs. The heritability (SNP-h2) for the ﬁrst and second disease are shown for each pAID pair (blue and green bars, respectively) along with the genetic
correlation (rG) for the pair estimated based on total autosomal common genetic variants (orange) and based on autosomal variants excluding the MHC
(red). Displayed are those pairs for which the rG estimates reached nominal signiﬁcance (Po0.05). P-values are based on restricted maximum likelihood
ratio test. Error bars represent standard error. (c) Genetic sharing using the genome-wide pairwise sharing statistic (GPS). Correlation plot of the P-values
obtained from the genome-wide pairwise shared analysis. Signiﬁcant P-values support evidence of genetic sharing based on the correlation of signiﬁcant
association ﬁndings reported by GWAS for each pair of diseases.
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the extended MHC was entirely removed from the analysis across
any of the pAID pairs, making it unlikely that the sharing of
common HLA alleles could signiﬁcantly account for the degree of
co-heritability observed (Fig. 2b).
Discussion
To our knowledge, this is the most comprehensive assessment of
heritability and disease prediction using genome-wide dense
genotyping data across multiple pAIDs. The results show that
SNP-h2 estimates were signiﬁcantly higher for the pAID cohorts
as compared with those obtained for the non-immune-mediated
disease EPI (Fig. 1a and Supplementary Tables 1 and 2). Among
the pAIDs examined where the SNP-h2 estimates were at least
nominally signiﬁcant (Po0.05), T1D and JIA were the most
highly heritable (Fig. 1b). These results are in keeping with the
SNP-h2 estimates reported for T1D and Rheumatoid Factor
Positive (RFþ ), Rheumatoid Arthritis (RA) in adults, using the
Wellcome Trust Case Control Consortium data sets17,26,31.
Considerably weaker SNP-h2 estimates were observed for UC
and CD, consistent with previous reports in adults32
(Supplementary Fig. 1A). Although the sample size of CD was
several fold greater than those of T1D and UC, and twice that for
JIA, the SNP-h2 estimates are lower in CD, suggesting that
environmental factors play a much larger role in CD disease
aetiology (Fig. 1d). This ﬁnding is in keeping with studies
demonstrating a key role for the gut microbiome and faecal ﬂora
in disease-onset and severity in the IBDs11,33,34.
As noted, the SNP-h2 observed for JIA was high despite the
known heterogeneous nature of this disease, including seven
distinct JIA subtypes35. Little is known about the heritability of
JIA as it is fairly uncommon. However, in RA, the more common
JIA counterpart in adults, a range of SNP-h2 estimates has been
reported17,26,31,36. Some of the heterogeneity in SNP-h2 estimates
for RA may be attributable to the different ratios of RFþ vs
RF patients across different study cohorts, as recent analyses
suggest that RFþ RA may be ‘distinct’ from RF forms of RA
in terms of genetic aetiology37. Moreover, the subphenotype of
JIA that is most similar to RFþ RA (i.e. RFþ JIA) made up only
a small component of our JIA cohort (4.9%). Thus, the high
estimated heritability observed in JIA suggests that despite the
heterogeneous clinical ﬁndings, there may be a strongly shared
genetic component contributing to a common aetiology.
We observed relatively low SNP-h2 estimates for SLE (Fig. 1b).
Although these estimates are lower than those reported by So
et al.,38,39 they are higher than the POP-h2 reported based on
sibling-recurrence40. These observations are consistent with strong
environmental and epigenetic components to SLE liability41,42. We
included in our analysis a non-immune-mediated disease, early-
onset EPI, as a comparator cohort. As expected, the SNP-h2
estimates on the liability scale, albeit non-zero, was relatively low
compared with any of the AI diseases. That we observed slightly
higher heritability estimates across our paediatric cohorts than
previously reported in adults is also in keeping with the notion that
paediatric-onset diseases have been noted previously to reﬂect
disease aetiologies with a stronger genetic component29 and less
confounding due to reduced timespan of environmental
exposure(s). Adult or late-onset AI diseases can be associated
with environmental precipitating factors such as viral infections or
drug exposures, which have been implicated in a range of AI
diseases including T1D, CEL and SLE3,42.
Although estimates for JIA and T1D are higher than
SNP-h2 estimates reported previously, our estimates for RA and
T1D are more consistent, although still falling short of, than those
reported by population estimates from twin-based or familial
studies (Supplementary Table 2). That these SNP-h2 based
estimates are in general still falling behind estimates made from
epidemiological studies illustrates the ‘missing heritability’ phe-
nomenon. Disparities between POP-h2 and SNP-h2 estimates may
be at least partially attributable to inﬂation of population-based
estimates in the presence of ascertainment-bias and/or insufﬁcient
adjustment for confounding effects. The latter tends to occur if
there are signiﬁcant non-additive or shared environmental factors
that contribute to phenotypic variation36,43.
A number of previous epidemiological and genetic studies
have suggested a signiﬁcant degree of shared risk across AI
diseases44–47. There are a number of reasons why our results may
differ from these reports. In such population-based studies,
observed sharing of risk in the population is inevitably
confounded by common environmental factors or gene–
environment interactions, neither of which would be parsed out
from purely epidemiological observations. In addition, it can be
challenging to perform these comparisons in heterogeneous
populations because they may be composed of different
underlying genetic backgrounds, and genetic ancestry is known
to dramatically affect the risk for many AI diseases (for example,
greater risk of CEL and JIA in Caucasians)4,20.
Although there are several prior large-scale analyses of genetic
sharing among AI diseases using GWAS data, these are based on
somewhat different analytical approaches or study methodology
than those employed here. A notable example comes from
Cotsapas et al., who derived a Cross-Phenotype Meta-Analysis
test statistic that powerfully combines multiple independent AI
data sets to analyse the likelihood that a SNP is shared across
disease phenotypes. They applied this test statistic to the 140 top
genetic risk variants reported previously by GWAS across seven
AI diseases47. Although there is no doubt that ﬁndings from this
study are informative, the targeted candidate approach has clear
limitations and only summary statistics were available. Another
concern, which is not unique to the study by Cotsapas et al., but a
concern in most large GWAS meta-analyses, is inter-study
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Figure 3 | Disease prediction using a support vector machine model.
Shown are the mean (orange) and maximum (blue) areas under the curve
(AUC) achieved in the validation set as obtained for each disease in the
ten-fold cross-validation analysis. The mean and maxima refer to the best
AUC’s when testing a range of P-value thresholds from which to pick SNPs
in training the linear SVM. SPA, spondyloarthropathy.
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heterogeneity these studies often combine summary data
obtained from independent case–control study cohorts accrued
and genotyped across North America and Europe using different
genotyping platforms and QC/analysis steps, requiring post-hoc
statistical adjustments for heterogeneity, genetic variation and the
use of SNP proxies. Although single-institution study designs can
have limited applicability, in our study, using a common shared
control accrued in the same institution and genotyped on the
same platform does limit the effect of inter-study heterogeneity in
our analysis.
As expected, we found that variations across the extended
MHC strongly contributed to both heritability estimates and
disease risk predictability in T1D and CEL, and more modestly in
UC and JIA. The contribution of the extended MHC to total
phenotypic variance explained correlated with the strength of the
strongest association signal within the extended MHC. However,
as recent reports have shown, this method for estimating h2 is
sensitive to the variation in linkage-disequilibrium (LD) across
the genome18,31. We therefore examined the effect of LD on the
SNP-h2 estimates by comparing the results with those obtained
using non-correlated SNP markers (Supplementary Fig. 2B; see
Methods for details). As anticipated, the effect of the pruning is
mostly attributable to the strong role of the MHC in the
heritability of these diseases, as pruning had little effect on the
heritability estimates once the extended MHC was removed.
Thus, the number and degree of LD for the input SNPs used for
calculating h2 can be important for diseases where theMHC plays
a major role, consistent with previous studies31,48,49.
The SNP-h2 for T1D was most strongly affected by the removal
of the extended MHC, emphasizing the importance of MHC
polymorphisms in T1D pathogenesis. In addition, the estimates
for SPA and CEL both fell signiﬁcantly when markers across the
MHC were excluded from further analysis. The relatively limited
contribution of the genetic polymorphisms across the MHC to
heritability in IBD was consistent with prior GWAS results,
as the MHC SNP (rs1626392, Po2.27 10 7) most signiﬁcantly
associated with CD did not reach genome-wide signiﬁcance,
deﬁned as Po5 10 8 (Supplementary Table 8). Aside from the
MHC, recent work has examined the degree to which functional
or coding loci, for example, DNAse I Hypersensitivity Sites50,
contribute to disease heritability. Such studies, currently
underway, will help delineate biological functions and connect
genetic associations with mechanistic roles of such functional
variants.
A still unrealized, but much anticipated goal of personalized
medicine is to utilize genomic data to accurately predict disease
risk26,51–53. We found that for the three pAIDs (T1D, JIA and
CEL) that were most predictable, a range of P-value thresholds
(Po1 10 6 and Po1 10 8) could be used to identify the
predictive SNPs without signiﬁcantly impacting maximum or
mean AUC achieved, suggesting that the SVM model was robust
to this parameter (Fig. 3 and Supplementary Table 11). In
comparison, we obtained fairly modest AUCs for CD, UC and
CVID (AUCmax40.7, AUCmean40.65). These are in keeping
with our expectation that genetic prediction should rest on
underlying genetic heritability and conﬁrms the value of SNP
heritability analysis.
Indeed, the above observations are perhaps not surprising,
given recent ﬁndings that support a strong contribution for
environmental factors in disease susceptibility. For example, host-
microbial interactions have been implicated in the pathogenesis
of IBD and RA11,54. Furthermore, in CVID, it is well-established
that although genetic risk factors play a role in disease risk, there
is signiﬁcant within-disease heterogeneity in terms of aetiology.
Patients with CVID are often diagnosed in late adolescence,
suggesting that environmental risk factors play a greater role.
Likewise, most cases of paediatric-onset IBD also have a post-
pubescent age of onset. This is in contrast to T1D, JIA or CEL,
which are commonly diagnosed by or before the age of 12 years,
although some degree of variability is observed. This is consistent
with the correlations noted above, in that the three diseases with
more moderate SNP-h2 estimates were also less predictable.
Among the three largest cohorts, namely JIA, UC and CD, CD
was by far the largest. However, the heritability estimated for CD
in our data set was the lowest of the three. As we know from prior
studies that disease prediction is a function of heritability, sample
size and the number of causal variants, we might expect the
accuracy of disease prediction for CD to be relatively poor. This is
exactly what we observed. In contrast, we had somewhat limited
sample sizes for SPA, PS and CEL cohorts, and we caution against
the interpretation of the high heritability estimates observed for
PS. Another limitation of the present study is that we have not
considered the role of rare, or potentially de novo, variants in the
overall estimates of genetic heritability. As more sequencing data
using either whole-exome or whole-genome approaches become
available, future studies will help address this question.
A unique opportunity provided by our cohort was the ability
to quantify pairwise pAID genetic correlations as numerous
epidemiological analyses have shown that subsets of pAIDs
co-cluster in families or exhibit high rates of comorbidity55–57
(Table 3). As pAID co-heritability has not been systematically
examined using genome-wide SNP data, we aimed to identify
pAIDs showing signiﬁcantly positive rG (that are consequently
co-heritable) versus diseases that are either genetically unrelated
or negatively correlated (and are consequently ‘mutually-
protective’). We calculated the rG for each pAID pair and
between each of the nine diseases and EPI. This latter analysis
provides a ‘control’ or contextual baseline, akin to the inclusion of
Table 3 | pAID joint heritabilities or genetic correlation (rG) reaching nominal signiﬁcance.
pAID pair rG (auto) s.e. Pval rG (exMHC) s.e. P_nominal P_adj
CVID-JIA 0.343 0.127 1.22E–03 0.354 0.142 2.47E–03 2.23E–02
EPI-JIA 0.150 0.079 2.95E–02 0.142 0.085 4.87E–02 0.44
EPI-UC 0.197 0.103 2.77E–02 0.248 0.108 1.06E–02 0.10
PS-T1D 0.241 0.139 3.29E–02 0.282 0.167 3.74E–02 0.34
PS-UC 0.316 0.169 2.31E–02 0.289 0.171 3.76E–02 0.34
SLE-CD 0.266 0.120 8.25E–03 0.255 0.121 1.15E–02 0.10
SPA-CD 0.215 0.138 4.64E–02 0.235 0.156 4.67E–02 0.42
T1D-CD 0.096 0.053 3.45E–02 0.142 0.064 1.33E–02 0.12
UC-CD 0.659 0.069 o1.00E–04 0.674 0.072 o1.00E–04 9.00E–04
Auto, autosomal; CD, crohn’s disease; CEL, celiac disease; CVID, common variable immunodeﬁciency disorder; EPI, epilepsy; JIA, juvenile idiopathic arthritis; NA, not applicable; pAID, paediatric
autoimmune disease; PS, psoriasis; exMHC, MHC excluded; SLE, systemic lupus erythematosus; SPA, spondyloarthropathy; T1D, type 1 diabetes; UC, ulcerative colitis.
P-values (P) are based on results from the restricted maximum likelihood estimate (likelihood ratio test). P_adj is made using a Bonferonni-adjustment for nine pairwise tests for each disease.
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CD as a ‘null comparator’ phenotype by the Psychiatric Genomics
Consortium20. We observed a strongly and moderately positive
rG between two pAID pairs, namely UC-CD and JIA-CVID.
Although the MHC made major contributions to the disease-
speciﬁc heritability, we found no evidence that variations across
the MHC signiﬁcantly contributed to the pAID co-heritability for
any of the investigated disease pairs (Fig. 2b). For the pAID pairs
with signiﬁcantly positive rG’s (UC-CD and JIA-CVID), we did
not observe a signiﬁcant reduction in rG estimates when the SNPs
within the MHC were removed from the analysis, making it
unlikely that genetic sharing of MHC haplotypes can explain the
genetic correlation observed among pAIDs in this data set
(Fig. 2b). In addition, that the UC-CD and JIA-CVID pairs were
the two with the largest positive rG is also consistent with results
we obtained using an independent genome-wide pairwise sharing
metric for genetic correlation, in which we considered all
genome-wide SNP markers except those within the extended
MHC locus (Fig. 2c, see Methods for details). Although it may
appear to be surprising given the known association with the
MHC across all pAIDs, these results are in keeping with our
ﬁnding that the most signiﬁcant MHC association signals
identiﬁed for each pAID was disease-speciﬁc and did not overlap
across the nine pAIDs (Supplementary Table 5).
Somewhat unexpectedly, we observed a negative marginal rG
across several pAID pairs, including SLE-CD, SPA-CD, PS-UC
and PS-T1D. Although none of these was signiﬁcant following a
Bonferroni correction, in each of the negatively correlated pAID
pairs, one of the two diseases is considered a ‘classic autoimmune’
(that is, SLE, UC, and T1D), whereas the other pAID in the pair
(that is, CD and PS) has been noted to have a strong
‘inﬂammatory’ component.
Taken together, we report genome-wide SNP genotype-derived
heritability estimates and genetic correlations of disease liability
across pairs of nine investigated pAIDs using common and low-
frequency genetic variants. We contextualized these ﬁndings
alongside a comprehensive review of available literature and
epidemiological data sets, illustrate a method for quantifying
genetic risk factor sharing across pAIDs and provide considera-
tions for how such genetic data can aid in disease prediction.
We observed that SNP-h2 estimates in pediatric AI diseases tend to
be greater in magnitude when compared to SNP-h2 reported
previously based on GWAS data from studies of adult AI disease
cohorts, particularly for T1D, UC, JIA/RA. Moreover, we also
observed that the ‘co-heritability’ across pAIDs was minimally
attributable to sharedMHC variations. While genomic screening in
the general population on a large scale is not currently feasible, or
of high utility (given the low disease prevalence and consequently,
limited positive predictive value as well as the limitations in
interpretability), our analysis suggests that there is a high
heritability and disease predictability across the pAIDs. Future
studies in larger sample sizes and in adult cohorts will be helpful in
validating these results and developing new and improved methods
for genome-based disease prediction and for the development of
novel biomarkers that can be used to predict pAID risk.
Methods
Study population. Information regarding the patient cohorts have been published
previously and are summarized brieﬂy below.
Cases and controls were either directly ascertained as described in prior
studies29,53,58–65 or obtained from de-identiﬁed samples and associated electronic
medical records (EMRs) residing in the genomics biorepository at the Children’s
Hospital of Philadelphia. EMR searches were conducted using previously described
algorithms58,59 based on phenotype mapping established using PheWAS ICD-9
code mapping tables53,58,60 in consultation with qualiﬁed physician specialists for
each disease cohort. All DNA samples were assessed for QC and genotyped on the
Illumina HumanHap550 or HumanHap610 platforms at the Center for Applied
Genomics (CAG) at the Children’s Hospital of Philadelphia (CHOP, Philadelphia,
Pennsylvania, USA). Note that the patient counts below refer to the total recruited
sample size from which we excluded non-qualiﬁed samples/genotypes that did not
pass QC criteria required for inclusion in the genetic analysis (for example, because
of relatedness or poor genotyping rate; see details below).
The IBD cohort comprised 2,796 individuals aged 2–17 years of European
ancestry with biopsy-proven disease, including 1,931 with CD and 865 with UC,
excluding all patients with unclassiﬁed type (IBD-U). Affected individuals were
recruited from multiple centres from four geographically discrete countries and
diagnosed before their nineteenth birthday according to the standard IBD
diagnostic criteria, as previously reported3,29.
The T1D cohort consisted of 1,120 cases from nuclear family trios (one affected
child and two parents), including 267 independent Canadian T1D cases collected
in paediatric diabetes clinics in Montreal, Toronto, Ottawa and Winnipeg (Canada)
and 203 T1D cases recruited at CHOP since September 2006. All patients were
Caucasians by self-report and ranged in age between 3 and 17 years, with 7.9 years
being the median age at onset. All patients have been treated with insulin since
diagnosis. Disease diagnosis was based on these clinical criteria, rather than any
laboratory tests.
The JIA cohort was recruited in the United States of America, Australia and
Norway and comprised of a total of 1,123 patients with onset of arthritis at
o16 years of age. JIA diagnosis and JIA subtype were determined according to the
International League of Associations for Rheumatology revised criteria35 and
conﬁrmed using the JIA Calculator software66 (http://www.jra-research.org/
JIAcalc/), an algorithm-based tool adapted from the International League of
Associations for Rheumatology criteria. Before standard QC procedures and
exclusion of non-European ancestry, the JIA cohort was comprised of 464 case
subjects from Texas Scottish Rite Hospital for Children (Dallas, Texas, USA)
and the Children’s Mercy Hospitals and Clinics (Kansas City, Missouri, USA)
of self-reported European ancestry; 196 subjects from the CHOP; 221 subjects
from the Murdoch Childrens Research Institute (Royal Children’s Hospital,
Melbourne, Australia) and 504 subjects from the Oslo University Hospital
(Oslo, Norway).
The CVID study population consisted of 223 patients from the Mount Sinai
School of Medicine (New York City, New York, USA); 76 patients from the
University of Oxford (London, England); 47 patients from the CHOP and 27
patients from the University of South Florida (Tampa, Florida). The diagnosis in
each case was validated against the ESID/PAGID diagnostic criteria, as previously
described67. Although the diagnosis of CVID is most commonly made in young
adults (aged 20–40 years), all of the CHOP and University of South Florida cases
had paediatric age of onset disease, whereas the majority of the cases from the
Mount Sinai School of Medicine and Oxford had onset in young adulthood.
We note that as the number of individuals with adult-onset CVID disease is so
small (less than 5% of all cases presented), and all ten diseases have paediatric age
of onset disease, we have elected to refer to the cohort material as pAIDs.
The balance of the paediatric AI disease subjects’ (SPA, PS, CEL and SLE)
samples were accrued by our biorepository at the CHOP, which includes over
60,000 paediatric patients recruited and enrolled by the Center for Applied
Genomics at CHOP. These individuals were ascertained for having a conﬁrmed
diagnosis of SPA, PS, CEL and SLE in the age range of 1–17 years during time of
diagnosis and were required to fulﬁll clinical criteria for these respective disorders,
as conﬁrmed by a specialist. Only cases that upon EMR search were conﬁrmed to
have at least two or more in-person visits, at least one of which is with the speciﬁed
ICD9 diagnosis code(s) were pursued for clinical conﬁrmation (see Supplementary
Table 12 for ICD-9 inclusion and exclusion codes). We used ICD9 codes previously
identiﬁed and utilized for PheWAS or EMR-based GWAS59,60 and agreed upon by
board-certiﬁed physicians.
Age- and gender-matched control subjects, including the EPI cohort of both
generalized and focal idiopathic EPI (ICD-9 345.9 and 345.4, respectively),
were identiﬁed from the CHOP-CAG biobank and ascertained by exclusion
of any patient with any ICD-9 codes for disorders of autoimmunity or
immunodeﬁciency58 (http://eicd9.com/). Research Ethics Boards at the CHOP and
each of the collaborating centre, including: the Mount Sinai School of Medicine,
University of Oxford, University of South Florida, the Children’s Mercy Hospitals
and Clinics, Texas Scottish Rite Hospital for Children, Murdoch Children’s
Research Institute, Oslo University Hospital, Cincinnati Children’s Hospital
Medical Center, McGill University, RCCS ‘Casa Sollievo della Sofferenza’,
University of Toronto, University of Edinburgh, Emory University, University of
Naples ‘Federico II’, Cedars Sinai Medical Center, Yorkhill Hospital for Sick
Children, University of Miami Miller School of Medicine, Careggi University
Hospital, University of Utah School of Medicine and Primary Children’s Medical
Center, approved this study.
Written informed consent was obtained from all subjects (or their legal
guardians). Genomic DNA extraction and sample QC before and following
genotyping were performed using standard methods61. To minimize confounding
because of population stratiﬁcation, we focused on only individuals of European
ancestry, as determined by both self-reported ancestry and principle component
analysis, PCA) in the present study (see below and Supplementary Fig. 4).
Genotyping and QC. All samples were genotyped at the CAG on the Human-
Hap550 or 610 BeadChip arrays. Although some published analyses using GWAS
data to derive heritability estimates have applied whole-genome imputation
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because of the presence of samples with non-matching platforms, this is not ideal
given (i) added risk of artefacts and (ii) consequent variations in coverage
(genotyping density) across the genome. Without adding signiﬁcant additional
information, this can result in biased heritability estimates unless careful
corrections are made to apply additional down-sampling/weighting of more
densely imputed regions31,48,49. As over 90% of the markers on the two arrays are
shared, whole-genome imputation was not necessary and we utilized only the set of
directly overlapping genotyped SNPs in the analysis (B500,000).
After extracting the overlapping SNPs from the two platforms, SNPs with a low
genotyping rate o95%, low MAF (o0.01) or signiﬁcantly departing from the
expected Hardy–Weinberg equilibrium (Po0.01) were excluded. Samples with low
average genotyping call rate (o95%) or determined to be of outliers of European
ancestry by PCA (Any of the top ten principal components (PCs) 46.0 standard
deviations as reported by SMARTPCA/EIGENSTRAT68) were removed. In
addition, one of each pair of distantly related individuals, as determined by
Identify-by-State analysis (40.05), was excluded, such that the largest sample size
would be retained in the ﬁnal cohort.
Web-based access to all novel data included in this manuscript is available
through our website at http://www.caglab.org.
Population stratiﬁcation correction. The ﬁnal cohort, following all above-noted
QC, included a total of 4,956 pAID cases inclusive of 9 pAIDs and 27,451
population-matched controls, as well as a cohort consisting of 819 cases of
paediatric-onset EPI. To avoid confounding, we assigned individuals ﬁtting the
diagnosis criteria for two or more pAIDs to the smaller disease cohort by sample
size. No individual was included twice. To ensure that the markers tested across the
cohorts were consistent, we included only SNPs that passed all QC criteria (461,301
SNPs). The ﬁltered SNPs were tested in cases and controls for association with
disease and used for the estimation of the genetic relationship matrix (see below).
We used a logistic regression equation to estimate ORs/betas, 95% conﬁdence
intervals and P-values for trend, using additive coding for genotypes (0,1,2 minor
alleles). We adjusted for gender and population stratiﬁcation by including the
binary gender and the ﬁrst ten PCs (GCTA) from the PCA calculated from a set of
100,000 pruned SNPs as covariates in the logistic regression analyses69. From the
results of the association testing, we determined the genomic inﬂation per disease-
common control cohort. All disease-speciﬁc, case–control GWAS had lGC values at
or below 1.04 with the exception of CD (1.09), consistent with that previously
reported for this data set29. Final counts from each pAID cohort, included controls
and genomic inﬂation calculated from median w2 association test statistics are
reported in Table 1.
Estimation of the variance components for each pAID. Only individuals and
SNPs that passed all QC metrics were used to estimate the variance components
for the ten diseases (nine pAIDs and one non-pAID condition EPI). For disease-
speciﬁc analysis, the common set of controls were used for each case–control
analysis cohort, after excluding individuals who are relatives up to within the
5th degree. The genetic relationship between individuals was estimated using
(i) all autosomal SNPs, (ii) all autosomal SNPs excluding the extended MHC
(chr6:26.5–34Mb) and (iii) SNPs only found on the X-chromosome (ChrX).
We applied the previously described linear mixed model method for estimating
whole-genome SNP-based heritability using both common and low-frequency
variants, which is implemented in the software GCTA. We estimated the
genetic variance associated with genome-wide SNPs on the observed scale
(SNP-heritability or SNP-h2)70, conditioning on the top 20 ancestry PCs derived
from a pruned set ofB100,000 independent SNPs across the same data set (that is,
PLINK --indep-pairwise 50 10 0.2) obtained also using GCTA. As our phenotypes
are dichotomous traits, we subsequently transformed these results to the liability
scale based on approximately observed disease prevalence at our centre for each
trait (Table 1). Note that the total control sample size utilized varied slightly as we
optimized our analysis to maximize the retained sample size when conservatively
removing distantly related individuals during QC. As we excluded rare variants
(MAFo0.01), these variants are therefore not included in the heritability estimates
attributable to genetic variation.
Joint heritability across pAID pairwise combinations. We estimated the genetic
correlation in disease risk for each of other pAID pairs using a bivariate linear
mixed model, as described previously17. For each pairwise analysis, the pooled
control samples passing QC were randomly allocated to the two diseases evenly
and the top 20 PCs were again included as covariates. By jointly analysing a pair of
cohorts, these results estimate both the SNP-h2 of liability to both diseases and an
estimate of the SNP-genetic correlation between these liabilities. We determined
the signiﬁcance of the rG using a likelihood ratio test by ﬁxing the genetic
correlation at zero17. Signiﬁcantly positive (or negative) rG’s should reﬂect a shared
(or disparate) genetic background, as a positive (negative) rG means that the
correlation in the genetic variance components are higher (lower) between case
subjects than between the case subjects and the respective control cohorts.
Genome-wide pairwise sharing analysis. We applied a novel test to detect the
presence of SNPs anywhere in the genome that are simultaneously associated with
each of two diseases; these SNPs are the genetic risk factors shared by that pair of
pAIDs. Most existing tests require choosing a signiﬁcance threshold to determine
which SNPs are associated with which disease, but it is unknown how best to
choose this threshold. Our method is threshold-free and requires no tuning
parameters. Speciﬁcally, for any two diseases, we converted the P-values for all
SNPs in the genome into Z-scores, such that for example:
X1; . . . ;Xn are the Z scores for D1 across n SNPs; ð1Þ
Y1; . . . ; Yn are the Z scores for D2 across n SNPs: ð2Þ
The test statistic, g, used to detect genetic sharing between two diseases is
g ¼ max
1jn
min xj
 ; yj
   ; ð3Þ
which is the maximum of the pairwise minima of the signals across all of the
n SNPs. The rationale is that if SNP j is associated with both D1 and D2, the
magnitudes of both Xj and Yj should be large. The more shared SNPs there are, the
greater the likelihood that the maximum of the pairwise minimal values will be
large. Under the null hypothesis that any genetic sharing is due only to chance,
g should be relatively small. We can obtain the P-value of this statistic by
permuting the labels of the Z-scores relative to each other in order to simulate the
null hypothesis. In fact, these P-values can be calculated analytically using a
hypergeometric distribution, and no actual permutation is needed. Note that no
signiﬁcance threshold is required. This test was performed for all 45 pairwise pAID
combinations (hence, the reported P-values are Bonferroni-adjusted for 45 inde-
pendent tests).
Disease prediction using a linear SVM. Given that we observed relatively high
rates of heritability across many of pAIDs, we sought to evaluate the utility of
genome-wide SNP data in predicting pAID disease liability, using a previously
described SVM pipeline that can be applied to GWAS results for a dichotomous
trait52.
We identiﬁed SNPs to be used as predictors based on the strength of association
with a given disease in a training set, testing graded P-value thresholds
(Po1 10 5, 1 10 6, 1 10 7, 1 10 8, 1 10 9) for selecting SNP
predictors, where the P-value is derived from the case–control association testing
using samples in the training data set. We used each set of SNPs passing the tested
threshold to then train the linear SVM model.
We then validated the SVM model by testing the accuracy of disease liability
predictions for each of the nine pAIDs in the remaining independent sample set.
We reported the prediction performance as the mean and maximum AUC
achieved in both the training and validation sets (Fig. 3 and Supplementary
Table 11).
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